Recorded Chinese product: 注射用细胞色素C注射用细胞色素C
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 成都通德药业有限公司Chinese legal name: 成都通德药业有限公司
主要成分Active Ingredients
- 细胞色素CXibao Sesu
药物知识说明
细胞色素C是一种在国家药监局注册认定的药品。标注生产企业为成都通德药业有限公司。
该药品暂无关联的活性成分信息。
该药品标注的生产企业为：成都通德药业有限公司Chinese legal name: 成都通德药业有限公司、成都通德药业有限公司Chinese legal name: 成都通德药业有限公司、成都通德药业有限公司Chinese legal name: 成都通德药业有限公司。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 注射用细胞色素C) is a medicine registered with the national drug regulatory authority. It is manufactured by Chinese legal name: 成都通德药业有限公司.
No active ingredient relationships are currently recorded for this product in MedicineGraph.
Manufacturers recorded for this product: 成都通德药业有限公司Chinese legal name: 成都通德药业有限公司, 成都通德药业有限公司Chinese legal name: 成都通德药业有限公司, 成都通德药业有限公司Chinese legal name: 成都通德药业有限公司.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 注射用细胞色素CRecorded Chinese product: 注射用细胞色素C
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 15MG15 mg
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
生产企业Manufacturer
- 成都通德药业有限公司Chinese legal name: 成都通德药业有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H51021218
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H51021218
Manufacturer
Chinese legal name: 成都通德药业有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H51021218
生产企业
成都通德药业有限公司(国产)
适应症
用于各种组织缺氧急救的辅助治疗，如一氧化碳中毒、催眠药中毒、氰化物中毒、新生儿窒息、严重休克期缺氧、脑血管意外、脑震荡后遗症、麻酸及肺部疾病引起的呼吸困难和各种心脏疾患引起的心肌缺氧的治疗。
用法用量
静脉注射或滴注，一次15MG-30MG，视病情轻重一日1-2次，每日30MG-60MG。静脉注射时，加25%葡萄糖注射液20ML混匀后缓慢。也可用5%-11%葡萄糖注射液或0.9%氯化钠注射液稀释后静脉滴注。
不良反应
本品可引起过敏反应。也可因制剂不纯，混有热原而不引起热原反应。
禁忌
对本品过敏者禁用。
注意事项
1、用药前需做过敏试验。皮试划痕法系用 0.03%溶液1滴，滴于前臂屈面皮肤上，用针在其上刺扎一下（单刺）或多下（多刺），至少量出血程度。皮内注射法系用0.03mg/ml溶液0.03-0.05ml皮内注射。均观察15-20分钟，单刺者局部红晕直径10mm以上或丘疹直径＞7mm以上，多刺和皮内注射者红晕直径15mm以上或丘疹直径10mm以上为阳性。皮试阳性者禁用。 2、中止用药后再继续用药时，过敏反应尤易发生，须再做皮试，且应用用药量较小的皮内注射法。
规格
15MG
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.